Chemours 과거 순이익 실적
과거 기준 점검 0/6
Chemours 의 수입은 연평균 -59.8%의 비율로 감소해 온 반면, Chemicals 산업은 연평균 3.4%의 비율로 감소했습니다. 매출은 연평균 2.7%의 비율로 감소해 왔습니다.
핵심 정보
-59.83%
순이익 성장률
-59.15%
주당순이익(EPS) 성장률
| Chemicals 산업 성장률 | 12.93% |
| 매출 성장률 | -2.67% |
| 자기자본이익률 | n/a |
| 순이익률 | -5.24% |
| 최근 순이익 업데이트 | 30 Jun 2026 |
최근 과거 실적 업데이트
Recent updates
Seeking Alpha • Aug 06
Chemours: Close To A 'Perfect' Rotation, With A 'Buy' In Q2 2026 (Rating Upgrade)
Summary Chemours is upgraded to 'BUY' with a $20 PT and $30 fair value, reflecting renewed upside after recent volatility. CC's recent rally was driven by sentiment, not fundamentals, but the company now shows improving liquidity, debt reduction, and solid EBITDA guidance. Risks remain from regulatory liabilities and elevated leverage, but CC's divestment plan and Opteon growth support a high-conviction turnaround thesis. At or below $15/share, CC offers 35-37% annual upside; at $20/share, the risk/reward remains attractive though more speculative. Read the full article on Seeking Alpha
내러티브 업데이트 • Aug 05
CC: PFAS Settlement Will Support Cleaner Operations And Stronger Future Outlook
Analysts have trimmed their Chemours price target from $21.00 to $19.00 as updated assumptions point to different expectations for fair value, profitability, growth and future P/E levels. What’s in the News for Chemours Chemours announced a settlement with the U.S. Environmental Protection Agency and the West Virginia Department of Environmental Protection to resolve claims related to PFAS discharges and other alleged non compliance at its Washington Works, Fayetteville Works, and Chambers Works facilities.
내러티브 업데이트 • Jul 22
CC: Regulatory Settlement And Margin Recovery Will Drive Re Rating Potential
Analysts have lowered their price target on Chemours to $24.67 from $26.33, citing updated assumptions that include a slightly higher discount rate, modestly adjusted revenue growth expectations, a small change in projected profit margins, and a revised future P/E multiple. What’s in the News for Chemours BMO Capital reiterated a Buy rating on Chemours with a US$26 price target, which is close to the current median Wall Street target of US$25, according to recent analyst reports.내러티브 업데이트 • Jul 06
CC: PFAS Settlement And Updated Outlook Will Shape Balanced Future Expectations
Analysts have raised their Chemours fair value estimate from $17.00 to $21.00, citing updated views on discount rate assumptions, revenue growth, profit margins and potential future P/E levels. What’s in the News for Chemours Chemours agreed to a multi-site PFAS settlement with the U.S. Environmental Protection Agency, the Department of Justice, the West Virginia Department of Environmental Protection, and multiple states, with total costs reported at more than US$450 million for penalties, mitigation projects, pollution controls, and community water initiatives.
내러티브 업데이트 • Jun 22
CC: Raised Margins And 2026 Outlook Will Support Further Earnings Upside
Analysts maintained their $30.00 price target on Chemours, citing updated assumptions for the discount rate, revenue growth, profit margin, and future P/E that together support keeping the prior valuation level. What’s in the News for Chemours Chemours issued earnings guidance for the second quarter of 2026, indicating an expected sequential change in consolidated net sales in a range of 15% to 20%, which the company links to seasonal trends.내러티브 업데이트 • Jun 04
CC: Regulatory Reset And Margin Rebound Will Drive Re Rating Potential
Analysts now cite improved assumptions for Chemours' fair value, discount rate, revenue growth, profit margin, and future P/E in raising their price target by about $10 per share. What's in the News Chemours shares fell on May 21, 2026 after the EPA eased refrigerant regulations put in place during the Biden administration, according to recent news reports.내러티브 업데이트 • May 15
CC: Cooling Alliance And 2026 Guidance Will Support Further Earnings Upside
Analysts have raised their price target for Chemours by $1 to $30, reflecting updated assumptions that include a slightly lower discount rate, modestly adjusted revenue growth expectations, a higher projected profit margin, and a reduced future P/E estimate. What's in the News Chemours issued earnings guidance for the second quarter of 2026, expecting consolidated net sales to be 15% to 20% higher sequentially, citing favorable seasonal trends (Corporate Guidance).분석 기사 • May 08
The Chemours Company Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts
It's been a mediocre week for The Chemours Company ( NYSE:CC ) shareholders, with the stock dropping 17% to US$22.41 in...내러티브 업데이트 • Apr 22
CC: Cooling Partnership And 2026 Outlook Will Support Further Earnings Upside
Analysts now cite slightly higher long term revenue growth, profit margin, and P/E assumptions as reasons for raising Chemours fair value estimate from $25.00 to $29.00 per share. What's in the News Chemours and 2CRSi entered a Joint Development Agreement following the qualification of Chemours' Opteon two phase immersion cooling fluid in current generation 2CRSi servers, aimed at advancing two phase cooling technologies for high density IT infrastructure and AI workloads (Key Developments).내러티브 업데이트 • Apr 08
CC: Share Repurchases And 2026 Outlook Will Support Earnings Upside
Analysts have raised their Chemours price target from $21.00 to $25.00, citing updated assumptions around revenue growth, profit margins, and a lower future P/E multiple as key drivers of the change. What's in the News Chemours completed its share repurchase program announced on May 2, 2022, buying back 10,342,722 shares (6.76%) for a total of $309.28 million, with no additional shares repurchased between October 1, 2025 and December 31, 2025 (Key Developments).내러티브 업데이트 • Mar 24
CC: PFAS Litigation Will Drive Cautious Outlook Despite Cooling Technology Partnership
Analysts have maintained their $17.00 price target for Chemours, citing updated assumptions that include a 10.25% discount rate, 3.37% revenue growth, a 13.84% profit margin, and a future P/E of 3.87x, which they state continue to support the prior fair value view. What's in the News Chemours reported that between October 1, 2025 and December 31, 2025, it repurchased 0 shares for US$0 under its existing program and indicated that it has completed the buyback of 10,342,722 shares, or 6.76%, for US$309.28 million under the authorization announced on May 2, 2022 (Key Developments).내러티브 업데이트 • Mar 09
CC: PFAS Legal Overhang And Cooling Partnership Will Shape Balanced Return Outlook
Analysts have raised their price target on Chemours from $13.00 to $17.00, citing updated assumptions around discount rate, revenue growth, profit margins, and future P/E that change their view of the company’s risk and earnings potential. What's in the News Chemours and 2CRSi entered a Joint Development Agreement after Chemours' Opteon two phase immersion cooling fluid was qualified in current generation 2CRSi servers, with a focus on advanced cooling for high density IT, AI, and next generation chips, and an emphasis on end user and environmental benefits.내러티브 업데이트 • Feb 22
CC: Earnings Outlook And PFAS Legal Overhang Will Shape Future Upside
Analysts have revised their Chemours price target from $18.00 to $21.00, citing updated assumptions around discount rate, revenue growth, profit margin and future P/E that slightly adjust the risk and earnings profile they are using in their models. What's in the News Chemours issued new Full Year 2026 earnings guidance, with management indicating an expectation for Net Sales growth in the 3% to 5% range.내러티브 업데이트 • Feb 08
CC: PFAS Class Action Risk Will Limit Future Shareholder Returns
Analysts have kept their Chemours fair value estimate steady at $13.00, with the latest price target grounded in unchanged fair value assumptions, along with updated views on discount rate, revenue growth, profit margin and future P/E levels. What's in the News On January 6, 2026, a Montana federal judge denied motions to dismiss a class action against DuPont/Chemours, 3M and several other gear and materials manufacturers related to alleged toxic PFAS chemicals in firefighter turnout gear.분석 기사 • Feb 03
The Chemours Company (NYSE:CC) Shares Fly 27% But Investors Aren't Buying For Growth
The The Chemours Company ( NYSE:CC ) share price has done very well over the last month, posting an excellent gain of...내러티브 업데이트 • Jan 25
CC: Legal Overhang And Margin Reset Will Shape Balanced Outlook
Analysts have trimmed their price target on Chemours to about US$16 from roughly US$18, pointing to adjustments in profit margin expectations and valuation multiples, even though assumptions for revenue growth and future P/E have shifted. What's in the News A Montana federal judge denied motions to dismiss a class-action lawsuit involving PFAS in firefighter turnout gear, allowing claims against DuPont/Chemours and other manufacturers to move forward, including Racketeer Influenced Corrupt Organizations (RICO) claims that will remain active pending a related Ninth Circuit decision (Lawsuits & Legal Issues).내러티브 업데이트 • Jan 11
CC: PFAS Lawsuit And Weaker Margins Will Restrain Future Shareholder Returns
Analysts have kept their Chemours fair value estimate steady at US$13.00. The latest price target update reflects adjusted assumptions around discount rate, revenue growth, profit margin and future P/E rather than a change in headline valuation.내러티브 업데이트 • Dec 26
CC: Future Profitability Challenges Will Temper Benefits Of Completed Share Buybacks
Analysts have modestly raised their price target on Chemours to 13.00 dollars, reflecting slightly stronger revenue growth expectations and higher assumed future valuation multiples, while this is partially offset by a more cautious view on long term profitability and risk. What's in the News Completed a share repurchase program totaling 10,342,722 shares, representing 6.76% of outstanding shares, for $309.28 million under the buyback announced on May 2, 2022 (Key Developments).내러티브 업데이트 • Dec 12
CC: Long-Term Margin Outlook Will Offset Near-Term Losses And Completed Buybacks
Analysts have raised their price target on Chemours from 11 dollars and 41 cents to 13 dollars, reflecting expectations for significantly stronger long term profit margins, despite slightly more conservative assumptions for revenue growth and valuation multiples. What's in the News Completed a share repurchase program totaling 10,342,722 shares, representing 6.76% of outstanding shares, for $309.28 million under the buyback announced on May 2, 2022 (Key Developments).내러티브 업데이트 • Nov 01
CC: Global Supply Agreements And Buybacks Will Drive Undervalued Shares Higher
Analysts have adjusted their price target for Chemours. They are maintaining the fair value estimate at $17.78, but have slightly increased the discount rate and are projecting a modest decrease in both expected revenue growth and profit margin based on recent outlook factors.내러티브 업데이트 • Oct 17
Low GWP Refrigerants And Advanced Materials Will Drive Future Success
Analysts have raised their price target for Chemours by $1.00, reflecting updated assumptions for modestly improved fair value and profit margin forecasts. What's in the News Chemours has entered into strategic agreements with SRF Limited to strengthen its global supply chain, enhance operational flexibility, and increase capacity for key materials such as fluoropolymers and fluoroelastomers (Key Developments).내러티브 업데이트 • Oct 03
Low GWP Refrigerants And Advanced Materials Will Drive Future Success
Analysts have raised their price target for Chemours from $15.44 to $16.78, citing improved profit margins and slight increases in projected revenue growth as key factors for the update. What's in the News Chemours signed strategic agreements with SRF Limited to strengthen its global supply chain, increase operational flexibility, and secure fluoropolymer and fluoroelastomer capacity for multiple industries (Client Announcements).내러티브 업데이트 • Sep 17
Low GWP Refrigerants And Advanced Materials Will Drive Future Success
The modest increase in Chemours’ Consensus Analyst Price Target reflects slightly higher forward P/E expectations, while the discount rate remains stable, resulting in a revised fair value of $15.44. What's in the News Chemours signed strategic agreements with SRF Limited to enhance global supply chain, increase operational flexibility, and access capacity for fluoropolymers and fluoroelastomers, with no upfront capital investment required.분석 기사 • Sep 03
The Chemours Company (NYSE:CC) Held Back By Insufficient Growth Even After Shares Climb 33%
The Chemours Company ( NYSE:CC ) shares have continued their recent momentum with a 33% gain in the last month alone...분석 기사 • Jul 26
Is It Time To Consider Buying The Chemours Company (NYSE:CC)?
The Chemours Company ( NYSE:CC ), is not the largest company out there, but it saw a significant share price rise of...분석 기사 • Jul 04
The Chemours Company's (NYSE:CC) Price Is Right But Growth Is Lacking After Shares Rocket 30%
The Chemours Company ( NYSE:CC ) shares have had a really impressive month, gaining 30% after a shaky period...분석 기사 • Jun 29
Chemours (NYSE:CC) Has No Shortage Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...분석 기사 • May 14
We Like The Quality Of Chemours' (NYSE:CC) Earnings
Despite posting healthy earnings, The Chemours Company's ( NYSE:CC ) stock has been quite weak. Along with the solid...분석 기사 • Apr 25
Is There An Opportunity With The Chemours Company's (NYSE:CC) 48% Undervaluation?
Key Insights The projected fair value for Chemours is US$23.71 based on 2 Stage Free Cash Flow to Equity Chemours is...매출 및 비용 세부 내역
매출 및 비용 세부 내역
Chemours가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.
순이익 및 매출 추이
| 날짜 | 매출 | 순이익 | 일반관리비 | 연구개발비 |
|---|---|---|---|---|
| 30 Jun 26 | 5,797 | -304 | 621 | 106 |
| 31 Mar 26 | 5,821 | -410 | 528 | 107 |
| 31 Dec 25 | 5,808 | -386 | 504 | 108 |
| 30 Sep 25 | 5,837 | -337 | 549 | 107 |
| 30 Jun 25 | 5,850 | -429 | 578 | 111 |
| 31 Mar 25 | 5,788 | 10 | 603 | 108 |
| 31 Dec 24 | 5,782 | 69 | 618 | 109 |
| 30 Sep 24 | 5,835 | 63 | 557 | 109 |
| 30 Jun 24 | 5,814 | 106 | 505 | 107 |
| 31 Mar 24 | 5,904 | -329 | 538 | 110 |
| 31 Dec 23 | 6,078 | -253 | 1,286 | 108 |
| 30 Sep 23 | 6,004 | -317 | 567 | 112 |
| 30 Jun 23 | 6,294 | -87 | 624 | 117 |
| 31 Mar 23 | 6,566 | 489 | 689 | 114 |
| 31 Dec 22 | 6,831 | 578 | 705 | 118 |
| 30 Sep 22 | 7,031 | 908 | 688 | 117 |
| 30 Jun 22 | 6,933 | 881 | 670 | 111 |
| 31 Mar 22 | 6,673 | 746 | 560 | 113 |
| 31 Dec 21 | 6,345 | 608 | 583 | 107 |
| 30 Sep 21 | 6,108 | 394 | 582 | 104 |
| 30 Jun 21 | 5,662 | 256 | 572 | 100 |
| 31 Mar 21 | 5,100 | 215 | 539 | 93 |
| 31 Dec 20 | 4,969 | 219 | 526 | 93 |
| 30 Sep 20 | 4,984 | -117 | 463 | 86 |
| 30 Jun 20 | 5,140 | -117 | 472 | 83 |
| 31 Mar 20 | 5,455 | -46 | 508 | 82 |
| 31 Dec 19 | 5,526 | -52 | 536 | 80 |
| 30 Sep 19 | 5,637 | 407 | 600 | 82 |
| 30 Jun 19 | 5,876 | 606 | 610 | 83 |
| 31 Mar 19 | 6,284 | 792 | 647 | 84 |
| 31 Dec 18 | 6,638 | 995 | 630 | 82 |
| 30 Sep 18 | 6,749 | 1,081 | 603 | 80 |
| 30 Jun 18 | 6,705 | 1,013 | 597 | 80 |
| 31 Mar 18 | 6,476 | 893 | 578 | 82 |
| 31 Dec 17 | 6,183 | 746 | 592 | 81 |
| 30 Sep 17 | 5,930 | 288 | 582 | 82 |
| 30 Jun 17 | 5,744 | 285 | 605 | 81 |
| 31 Mar 17 | 5,540 | 106 | 616 | 76 |
| 31 Dec 16 | 5,400 | 7 | 591 | 81 |
| 30 Sep 16 | 5,438 | 151 | 605 | 89 |
| 30 Jun 16 | 5,526 | -82 | 615 | 87 |
| 31 Mar 16 | 5,651 | -82 | 598 | 97 |
| 31 Dec 15 | 5,717 | -90 | 632 | 97 |
| 30 Sep 15 | 5,906 | 75 | 634 | 101 |
양질의 수익: CC 은(는) 현재 수익성이 없습니다.
이익 마진 증가: CC는 현재 수익성이 없습니다.
잉여현금흐름 대비 순이익 분석
과거 순이익 성장 분석
수익추이: CC은 수익성이 없으며 지난 5년 동안 손실이 연평균 59.8% 증가했습니다.
성장 가속화: 현재 수익성이 없어 지난 1년간 CC의 수익 성장률을 5년 평균과 비교할 수 없습니다.
수익 대 산업: CC은 수익성이 없어 지난 해 수익 성장률을 Chemicals 업계(-0.9%)와 비교하기 어렵습니다.
자기자본이익률
높은 ROE: CC의 부채가 자산을 초과하여 자본 수익률을 계산하기 어렵습니다.
총자산이익률
투하자본수익률
우수한 과거 실적 기업을 찾아보세요
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/08/09 06:43 |
| 종가 | 2026/08/07 00:00 |
| 수익 | 2026/06/30 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
The Chemours Company는 18명의 분석가가 다루고 있습니다. 이 중 9명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| null null | Alembic Global Advisors |
| David Coleman | Argus Research Company |
| Michael Leithead | Barclays |